One‐year follow‐up results from AUGMENT‐HF: a multicentre randomized controlled clinical trial of the efficacy of left ventricular augmentation with Algisyl in the treatment of heart failure
Open Access
- 11 November 2015
- journal article
- research article
- Published by Wiley in European Journal of Heart Failure
- Vol. 18 (3), 314-325
- https://doi.org/10.1002/ejhf.449
Abstract
Aims AUGMENT‐HF was an international, multicentre, prospective, open‐label, randomized, controlled evaluation testing the hypothesis that Algisyl (injectable calcium alginate hydrogel) is superior to standard medical therapy (SMT) for improving functional capacity and clinical outcomes in patients with advanced heart failure (HF). We previously reported results following 6 months of follow‐up. This report presents the results from 1 year of extended follow up for this clinical trial. Methods and results We enrolled 78 patients with advanced HF, randomized (1:1), to Algisyl with SMT or SMT alone as previously reported. Patient inclusion criteria were LVEF ≤35%, peak VO2 of 9.0–14.5 mL/min/kg and LV end‐diastolic diameter (LVEDD) index 30–40 mm/m2 (LVEDD/body surface area). Patients must have been on stable, evidence‐based therapy for HF. A total of 58 patients, mean age 62.3 ± 9.6 years, with ischaemic (57.7%) or non‐ischaemic (42.3%) HF completed 12 months of follow‐up. Treatment with Algisyl was associated with improved peak VO2 at 12 months; treatment effect vs. control of +2.10 mL/kg/min (95% confidence interval 0.96–3.24, P < 0.001). Statistically significant improvements were observed for VO2 at anaerobic threshold, 6‐min walk test distance, and NYHA functional class (all P < 0.001). Through 12 months of follow‐up there were 4 (10.5%) deaths in the control group and 9 (22.5%) deaths in the Algisyl group. Conclusions Algisyl in addition to SMT was more effective than SMT alone for providing sustained 1‐year benefits in exercise capacity, symptoms, and clinical status for patients with advanced HF. These data support larger clinical evaluations of this novel therapy.Keywords
Funding Information
- Lonestar Heart, Inc.
This publication has 18 references indexed in Scilit:
- Augmentation of Left Ventricular Wall Thickness With Alginate Hydrogel Implants Improves Left Ventricular Function and Prevents Progressive Remodeling in Dogs With Chronic Heart FailureJACC: Heart Failure, 2013
- Modest Increase in Peak VO 2 Is Related to Better Clinical Outcomes in Chronic Heart Failure PatientsCirculation: Heart Failure, 2012
- Cardiopulmonary Exercise Testing in Patients with Chronic Heart Failure: Prognostic Comparison from Peak VO2 and VE/VCO2 Slope~!2010-04-07~!2010-04-26~!2010-05-26~!The Open Cardiovascular Medicine Journal, 2010
- Restoration of left ventricular geometry and improvement of left ventricular function in a rodent model of chronic ischemic cardiomyopathyThe Journal of Thoracic and Cardiovascular Surgery, 2009
- The reproducibility and sensitivity of the 6-min walk test in elderly patients with chronic heart failureEuropean Heart Journal, 2005
- Six minute corridor walk test as an outcome measure for the assessment of treatment in randomized, blinded intervention trials of chronic heart failure: a systematic reviewEuropean Heart Journal, 2005
- HEART FAILURE: Epidemiology, aetiology, and prognosis of heart failureHeart, 2000
- Reverse Remodeling From Cardiomyoplasty in Human Heart FailureCirculation, 1995
- Left Ventricular Aneurysm: A New Surgical ApproachThe Thoracic and Cardiovascular Surgeon, 1989